Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
Novo Nordisk Finds A New Way To Rival Eli Lilly. But Shares Tumble.
10:05am, Monday, 24'th Mar 2025
Novo Nordisk stock dropped Monday after the drugmaker licensed a Chinese competitor's weight-loss drug for $200 million up front. The post Novo Nordisk Finds A New Way To Rival Eli Lilly.
FINAL NVO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Novo Nordisk A/S Investors to Join the Class Action Lawsuit
10:00am, Monday, 24'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordi
Is Ozempic maker Novo Nordisk losing to Eli Lilly in the obesity wars?
09:31am, Monday, 24'th Mar 2025
Eli Lilly and Co (NYSE:LLY) is tightening its grip on the obesity drug market, with its injectable treatment Zepbound gaining momentum over Novo Nordisk's Wegovy, according to Berenberg. The investmen
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Lawsuit - NVO
09:30am, Monday, 24'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
09:00am, Monday, 24'th Mar 2025
SAN FRANCISCO, CA / ACCESS Newswire / March 24, 2025 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Novo Nordisk A/S. ("Novo" or the "Company") (NYSE:NV
SAP takes crown from Novo Nordisk as Europe's largest companby
08:51am, Monday, 24'th Mar 2025
German software giant SAP has overtaken Denmark's Novo Nordisk (NYSE:NVO) to become Europe's largest company by market cap. SAP's market cap of $340 billion edged past the maker of weightloss drugs,
5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes
08:30am, Monday, 24'th Mar 2025
The majority of U.S. stock indices ended barely in the green on March 21, 2025, overcoming their recent losing streaks since investors remain wary about the long-term economic impacts of President Tru
Novo Nordisk expands discounted Wegovy to all cash-paying US customers
08:07am, Monday, 24'th Mar 2025
Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a discounted price of $499 per month at their local pharmacy.
Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
08:00am, Monday, 24'th Mar 2025
The Wegovy® savings offer is good for all dose strengths of Wegovy® Eligible cash-paying patients can redeem this offer at the retail pharmacy of their choice PLAINSBORO, N.J. , March 24, 2025 /PRNe
Novo Nordisk secures license to weight-loss drug candidate from China's United Labs
06:21am, Monday, 24'th Mar 2025
China-based United Laboratories International said on Monday it will license its weight-loss drug candidate to Danish drugmaker Novo Nordisk in a deal worth up to $2 billion.
Guangdong, China and Bagsværd, Denmark, 24 March 2025 –The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL's w
The Gross Law Firm Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
05:45am, Monday, 24'th Mar 2025
NEW YORK , March 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class peri
Germany's SAP overtakes Novo Nordisk as Europe's largest company
05:20am, Monday, 24'th Mar 2025
German software company SAP overtook Danish healthcare company Novo Nordisk as Europe's largest company by market cap on Monday.
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
02:36am, Monday, 24'th Mar 2025
Novo Nordisk's latest trial results for its next-generation obesity drug CagriSema disappointed investors by failing to show superior outcomes to existing drugs. CagriSema, which includes a nascent fo
